Profile data is unavailable for this security.
About the company
SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE) and its product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is also developing drugs such as SM17, which has the potential to treat atopic dermatitis (AD), asthma, idiopathic pulmonary fibrosis (IPF) and other immune diseases, and SN1011, which targets systemic lupus erythematosus (SLE), pemphigus, multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD).
- Revenue in HKD (TTM)0.00
- Net income in HKD-163.29m
- Incorporated2001
- Employees61.00
- LocationSinoMab BioScience LtdUnits 303 and 305 to 307No.15 Science Park West AvenueHong Kong Hong KongHKG
- Phone+852 34269833
- Websitehttps://www.sinomab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Beijing Biostar Pharmaceuticals Co Ltd | -100.00bn | -100.00bn | 1.37bn | 147.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.85 | -- | 24.19 | -- | -- | -- |
| Dawnrays Pharmaceutical (Holdings) Ltd | 1.26bn | 199.64m | 1.82bn | 1.12k | 9.13 | 0.4867 | 6.15 | 1.44 | 0.1326 | 0.1326 | 0.8362 | 2.49 | 0.2809 | 2.47 | 7.96 | 1,064,644.00 | 4.36 | 10.98 | 5.07 | 13.75 | 45.76 | 55.52 | 15.53 | 32.76 | 4.21 | -- | 0.0028 | 31.01 | -7.89 | 2.22 | 73.29 | 17.20 | 17.13 | 2.69 |
| Cutia Therapeutics | 283.20m | -534.29m | 1.86bn | 298.00 | -- | 1.92 | -- | 6.56 | -1.70 | -1.70 | 0.9013 | 2.67 | 0.1908 | 2.55 | 5.57 | 850,454.10 | -36.00 | -- | -44.42 | -- | 34.92 | -- | -188.66 | -- | 2.92 | -- | 0.2774 | -- | 103.17 | -- | 77.91 | -- | -- | -- |
| Zhaoke Ophthalmology Ltd | 40.00m | -314.86m | 1.90bn | 270.00 | -- | 0.979 | -- | 47.40 | -0.5691 | -0.5691 | 0.0724 | 3.53 | 0.0159 | 1.38 | 9.25 | 136,057.50 | -12.50 | -38.02 | -14.65 | -41.79 | 49.28 | -- | -787.13 | -4,412.89 | 4.36 | -29.83 | 0.1373 | -- | 269.73 | -- | 38.32 | -- | 18.80 | -- |
| Jbm (Healthcare) Ltd | 812.98m | 216.39m | 2.29bn | 412.00 | 10.50 | 2.13 | 8.26 | 2.82 | 0.2657 | 0.2657 | 0.9984 | 1.31 | 0.5111 | 3.76 | 5.05 | 2,913,918.00 | 14.09 | 6.57 | 17.00 | 7.83 | 56.76 | 47.82 | 27.56 | 16.60 | 2.41 | -- | 0.2486 | 53.40 | 20.65 | 15.44 | 51.20 | 36.90 | 35.96 | -- |
| Hangzhou Jiuyuan Genetic Biopharm Co Ltd | 1.48bn | 139.63m | 2.31bn | 1.63k | 14.82 | 1.30 | 12.42 | 1.57 | 0.6464 | 0.6464 | 7.23 | 7.36 | 0.7509 | 1.55 | 2.17 | 958,496.20 | 7.10 | -- | 8.88 | -- | 81.67 | -- | 9.45 | -- | 4.03 | 46.31 | 0.1058 | -- | 6.35 | -- | 15.72 | -- | -- | -- |
| Golden Throat Holdings Group Co Ltd | 1.11bn | 303.31m | 2.35bn | 842.00 | 7.75 | 1.72 | 6.90 | 2.12 | 0.4103 | 0.4103 | 1.50 | 1.85 | 0.467 | 2.29 | 5.32 | 1,268,143.00 | 12.78 | 11.71 | 21.02 | 16.75 | 76.42 | 73.08 | 27.37 | 25.87 | 1.73 | 21.95 | 0.3616 | 94.67 | 23.26 | 8.25 | 27.37 | 13.71 | -12.27 | 34.38 |
| Essex Bio-Technology Ltd | 1.73bn | 313.18m | 2.52bn | 1.43k | 8.08 | 1.11 | 6.81 | 1.45 | 0.5508 | 0.5508 | 3.05 | 4.01 | 0.5596 | 2.96 | 2.84 | 1,196,360.00 | 10.10 | 10.28 | 13.56 | 13.62 | 89.50 | 87.73 | 18.05 | 18.70 | 1.82 | -- | 0.1135 | 17.49 | -3.87 | 5.47 | 11.61 | 0.3101 | -7.47 | 7.14 |
| Jacobson Pharma Corporation Ltd | 1.53bn | 302.58m | 2.54bn | 1.79k | 8.36 | 1.14 | 5.63 | 1.66 | 0.1519 | 0.1519 | 0.7698 | 1.12 | 0.4299 | 2.54 | 9.06 | 876,757.00 | 8.48 | 4.83 | 10.29 | 6.17 | 44.30 | 41.26 | 19.73 | 14.85 | 0.9023 | 10.21 | 0.286 | 57.09 | 7.43 | 0.0691 | 43.09 | 7.05 | 24.09 | 14.87 |
| SinoMab Bioscience Ltd | 0.00 | -163.29m | 2.70bn | 61.00 | -- | 8.53 | -- | -- | -0.1508 | -0.1508 | 0.00 | 0.2285 | 0.00 | -- | -- | 0.00 | -18.46 | -22.26 | -24.62 | -25.68 | -- | -- | -- | -3,832.94 | -- | -7.82 | 0.6265 | -- | 48.42 | -- | 23.85 | -- | -0.376 | -- |
| AIM Vaccine Co Ltd | 1.43bn | -304.43m | 3.90bn | 1.49k | -- | 1.04 | -- | 2.73 | -0.2504 | -0.2504 | 1.17 | 3.05 | 0.174 | 0.7724 | 1.12 | 930,483.40 | -3.71 | -8.04 | -6.66 | -12.31 | 71.80 | 79.64 | -21.32 | -39.38 | 0.5882 | -3.70 | 0.3341 | -- | 8.22 | 6.19 | 78.69 | -- | -7.20 | -- |
Data as of Feb 16 2026. Currency figures normalised to SinoMab BioScience Ltd's reporting currency: Hong Kong Dollar HKD
0.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 399.80k | 0.03% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 270.00k | 0.02% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 240.00k | 0.02% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 85.20k | 0.01% |
More ▼
Data from 30 Jun 2025 - 30 Jun 2025Source: FactSet Research Systems Inc.
